GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Halberd Corp (OTCPK:HALB) » Definitions » Current Deferred Taxes Liabilities

Halberd (Halberd) Current Deferred Taxes Liabilities : $0.00 Mil (As of Jul. 2023)


View and export this data going back to 2009. Start your Free Trial

What is Halberd Current Deferred Taxes Liabilities?

Current Deferred Taxes Liabilities represent future tax liabilities, resulting from temporary differences between book (accounting) value of assets and liabilities and their tax value, or timing differences between the recognition of gains and losses in financial statements and their recognition in a tax computation. Deferred tax liabilities generally arise where tax relief is provided in advance of an accounting expense, or income is accrued but not taxed until received.

Halberd's current deferred tax liabilities for the quarter that ended in Jul. 2023 was $0.00 Mil.

Halberd Current Deferred Taxes Liabilities Historical Data

The historical data trend for Halberd's Current Deferred Taxes Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Halberd Current Deferred Taxes Liabilities Chart

Halberd Annual Data
Trend Jul08 Jul22 Jul23
Current Deferred Taxes Liabilities
- - -

Halberd Semi-Annual Data
Jul08 Jul22 Jul23
Current Deferred Taxes Liabilities - - -

Halberd Current Deferred Taxes Liabilities Related Terms

Thank you for viewing the detailed overview of Halberd's Current Deferred Taxes Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.


Halberd (Halberd) Business Description

Industry
Traded in Other Exchanges
N/A
Address
P.O. Box 25, Jackson Center, PA, USA, 16133
Halberd Corp is a research-based biotechnology company seeking to discover and develop medical treatments for a range of diseases. The Company's extracorporeal treatment is designed to treat hard-to-cure blood-borne, neurologic and infectious diseases. The Company's patented methodology removes the appropriate bodily fluid from the patient, in a continuous fashion, like dialysis, or in a batch process, like blood sample testing.
Executives
John Christopher Maddox director, 10 percent owner, officer: President, COO, Treasurer and, other: Interim CFO 10755 VERNON, HUNTINGTON WOODS MI 48070
Mark Sven Lundquist director, 10 percent owner, officer: CEO, Secretary and Director 24655 TUDOR LANE, FRANKLIN MI 48025
Cocco Nicholas A. Jr. director 50104 N. JIMMY COURT, CHESTERFIELD MI 48047-1898
Leland Michael Thomas director 280 LASALLE PLACE, GROSSE POINTE FARMS MI 88236